医护人员在呼吸道合胞病毒感染治疗期间接触利巴韦林的情况。

Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections.

作者信息

Bradley J S, Connor J D, Compogiannis L S, Eiger L L

机构信息

Department of Pediatrics, University of California, San Diego, La Jolla 92093.

出版信息

Antimicrob Agents Chemother. 1990 Apr;34(4):668-70. doi: 10.1128/AAC.34.4.668.

DOI:10.1128/AAC.34.4.668

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC171665/

Abstract

Health care workers (HCW) are exposed to ribavirin aerosol during therapy of infants with respiratory syncytial virus infections. To assess the degree of HCW exposure, we analyzed air samples from patient rooms and HCW personal breathing zones during ribavirin aerosol delivery by ventilator (two samples), oxygen hood (two samples), and a new vacuum exhaust hood (four samples). HCW exposure to ribavirin during aerosol delivery by ventilator or vacuum exhaust hood system was substantially lower than HCW exposure during aerosol delivery by oxygen hood in rooms with adequate ventilation.

摘要

医护人员在治疗呼吸道合胞病毒感染的婴儿时会接触到利巴韦林气雾剂。为评估医护人员的接触程度，我们分析了在使用呼吸机（两个样本）、氧气头罩（两个样本）和新型真空排气头罩（四个样本）进行利巴韦林气雾剂给药期间，病房和医护人员个人呼吸区域的空气样本。在通风良好的房间里，通过呼吸机或真空排气头罩系统进行气雾剂给药时医护人员接触利巴韦林的程度明显低于通过氧气头罩给药时医护人员的接触程度。

相似文献

1

Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections.

Antimicrob Agents Chemother. 1990 Apr;34(4):668-70. doi: 10.1128/AAC.34.4.668.

2

Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections.

Antimicrob Agents Chemother. 1987 Jul;31(7):1143-6. doi: 10.1128/AAC.31.7.1143.

3

Evaluation of exposure of health care personnel to ribavirin.

J Toxicol Environ Health. 1989;28(1):1-12. doi: 10.1080/15287398909531324.

4

In vivo inhibition of respiratory syncytial virus by ribavirin.

Antimicrob Agents Chemother. 1982 Jan;21(1):125-30. doi: 10.1128/AAC.21.1.125.

5

Efficacy of ribavirin aerosol treatment for respiratory syncytial virus bronchiolitis in infants.

J Int Med Res. 1987 Jul-Aug;15(4):227-33. doi: 10.1177/030006058701500406.

6

Ribavirin for influenza and respiratory syncytial virus infections.

Lancet. 1983 Sep 3;2(8349):554-5.

7

Vapors, viruses, and views. Ribavirin and respiratory syncytial virus.

Am J Dis Child. 1986 Apr;140(4):331-2. doi: 10.1001/archpedi.1986.02140180065025.

8

Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice.

Antiviral Res. 1987 May;7(4):211-20. doi: 10.1016/0166-3542(87)90029-5.

9

Clinical review of ribavirin.

Infect Control. 1987 May;8(5):215-8. doi: 10.1017/s0195941700065978.

10

The exposure of health care workers to ribavirin aerosol.

JAMA. 1989 Apr 7;261(13):1880-1. doi: 10.1001/jama.1989.03420130042015.

引用本文的文献

1

Antiviral agents against respiratory viruses.

Clin Microbiol Newsl. 2001 Nov 1;23(21):163-170. doi: 10.1016/S0196-4399(01)89050-4. Epub 2001 Dec 24.

2

The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.

Virol Sin. 2015 Oct;30(5):371-8. doi: 10.1007/s12250-015-3630-3. Epub 2015 Oct 22.

3

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Adv Drug Deliv Rev. 2015 May;85:65-82. doi: 10.1016/j.addr.2014.11.004. Epub 2014 Nov 12.

4

Ribavirin: is there a risk to hospital personnel? Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

CMAJ. 1991 Feb 1;144(3):285-6.

本文引用的文献

1

Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.

Antimicrob Agents Chemother. 1983 Nov;24(5):696-701. doi: 10.1128/AAC.24.5.696.

2

Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants.

Pediatrics. 1983 Nov;72(5):613-8.

3

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

N Engl J Med. 1983 Jun 16;308(24):1443-7. doi: 10.1056/NEJM198306163082403.

4

Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease.

JAMA. 1985 Dec 6;254(21):3047-51.

5

Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections.

Antimicrob Agents Chemother. 1987 Jul;31(7):1143-6. doi: 10.1128/AAC.31.7.1143.

6

Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic.

Pediatr Infect Dis J. 1987 Feb;6(2):152-8. doi: 10.1097/00006454-198702000-00003.

7

Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease.

Pediatr Infect Dis J. 1987 Feb;6(2):159-63. doi: 10.1097/00006454-198702000-00004.

8

Cross-species extrapolations and the biologic basis for safety factor determinations in developmental toxicology.

Regul Toxicol Pharmacol. 1988 Mar;8(1):22-36. doi: 10.1016/0273-2300(88)90004-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。